MedTrace Logo

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-21

No results posted yet for this study

Summary

PER977 administration following a single dose of enoxaparin

Conditions

  • Healthy

Interventions

DRUG

PER977

reversal of edoxaban-induced anticoagulation

DRUG

Placebo

Reversal of edoxaban-induced anticoagulation

DRUG

enoxaparin

Sponsors & Collaborators

  • Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Scott Rasmussen, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206100 on ClinicalTrials.gov